Özet:

BISFOSFONATES are commonly used in the treatment of postmenopausal, corticosteroid increased osteoporosis, Paget disease, malignity and osteolysis associated hypercalcemia and metastatic bone diseases. Bifosphonate-related osteonecrosis may lead to serious oral complications such as bone marrow (BRONJ), osteomyelitis, necrotic bone disclosure. Dentists should be aware of these complications and should show the necessary consistency in the patient group that sees the treatment of this drug, which causes disorder in the healing of wounds due to defective osteoclastic function, reduced bone tissue vascularity. Method and Requirements: This study is a retrospective study of BRONJ found in cancer patients. The analyzed data includes age, gender, the cause of the disease, medical and dental history, the type of bifosphonates (BP). The local and systemic risk factors, clinical and radiological findings, therapeutic strategies of our patients diagnosed with BRONJ have been evaluated. The most common clinical outcomes of osteonekrosis were infection in the mandibules and necrotic bones. Related events included toothbrush, infection and trauma. Despite surgery, antibiotic therapy, hyperbaric oxygen therapy and the use of topical oral gargaras, some injury did not respond well to the treatment. Patients with infection have been re-operated or palliative treatment has begun. The results of this study confirmed toothbrushing and the fact that proteins are risk factors in the development of BRONJ. Before Bifosphonate begins, patients need to have a comprehensive dental examination. Patients with dental problems should be carried out in dental care before these medications begin.

Anahtar Kelimeler: